A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution, Transgene Expression, Safety and Efficacy in Non-Human Primates

Peter Francis¹, Christian Burns¹, Paul Szymanski¹, Nima Mohaghegh¹, Christopher Schmitt¹, Austin Klein¹, Roxanne Croze¹, Melissa A. Calton¹, Devi Khoday¹, Melissa Kotterman, Ph.D.¹, Katherine Barglow¹, David Schaffer¹,², David Kirn¹

¹ 4D Molecular Therapeutics, Emeryville, CA
² University of California, Berkeley, CA
Legal Disclaimer

This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operations, future financial position, prospects, plans, and objectives of management, are forward looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation.

This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied.

This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
Presenter Disclosures

- Chief Scientific Officer & a full-time employee at 4D Molecular Therapeutics, Inc.

- Inventor on patents and pending patent applications related to AAV capsid variants and AAV gene delivery.
Disease Background & Current Treatment

DURABLE EXPRESSION BY AAV GENE THERAPY HOLDS PROMISE

- Wet Age-Related Macular Degeneration (wet AMD)
- Diabetic Macular Edema (DME)
- Both Associated With:
  - Retina swelling & edema
  - Bleeding
  - Reduced visual acuity
- Stimulated by VEGF family members:
  - A, B & C isoforms & PIGF
- Current treatment:
  - IVT injection of anti-VEGF proteins
4D-150 for Wet AMD & DME
DUAL TRANSGENE, INTRAVITREAL GENE THERAPY INHIBITING FOUR DISTINCT VEGF FAMILY MEMBERS

HIGH UNMET MEDICAL NEED
- Frequent Injections
- Patient / Physician Adherence Issues
- Incomplete Responders

DIFFERENTIATION
Transduces Entire Retina Surface
Routine & Safe
One-time Intravitreal Administration
Inhibits 4 Targets

EPIDEMIOLOGY: US
- Wet AMD: ~200,000/yr incidence
- DME: ~1.2M prevalence

PRODUCT DESIGN
- Vector: R100
- Transgene 1: Aflibercept
- Transgene 2: VEGF-C RNAi
- Promoter: Ubiquitous

STATUS:
IND-Enabling Studies

EXPECTED MILESTONE:
Initiate Clinical Trial in 2H21
4D-150 Multi-Mechanistic Gene Therapy for Wet AMD & DME

DUAL TRANSGENE, INTRAVITREAL GENE THERAPY INHIBITING FOUR DISTINCT VEGF FAMILY MEMBERS

Abbreviations: VEGF, vascular endothelial growth factor; RPE, retinal pigment epithelium.
4D-150 Designed to Induce Regression of Neovascularization & For Resolution of Edema
R100 Structure & Target Vector Profile

**INTRAVITREAL DELIVERY FOR RETINAL DISEASES**

- Naturally occurring capsid
- R100

**Abbreviations:**
- ILM, inner limiting membrane
- RPE, retinal pigment epithelium

**Legend:**
- Blue: Capsid base
- Red: Peptide insertions
- Gray: Point mutations (internal)

**Diagram Notes:**
- Conventional naturally occurring vectors
- Blocked by barrier (e.g., ILM)
- Limited retinal transduction
- Overcome barrier (e.g., ILM)
- Enhanced retinal transduction

Abbreviations: ILM, inner limiting membrane; RPE, retinal pigment epithelium.
R100 Vector Proof-of-Concept

INTRAVITREAL TRANSDUCTION OF NHP RETINA & HUMAN RETINAL RPE CELLS VS AAV2 IN VITRO

Human RPE
in vitro

IVT in NHP
in vivo

Eye cross section
Retina
Vitreous body

Marker gene
Cell nuclei

AAV2
R100

*p < 0.05

EGFP+/PMEL17+ (%)

MOI

50 500 5000

0 20 40 60 80 100

R100
AAV2
Intravitreal 4D-150 Prototype: Stable Anti-VEGF Expression

R100.ANTI-VEGF EXPRESSION THROUGH 6 AND 12 MONTHS

- Laser-induced CNV 6 weeks after single IVT delivery of 4D-150 prototype*
- Dose-related sustained anti-VEGF expression at 6 and 12 months

*4D-150 Prototype = R100.anti-VEGF
Intravitreal 4D-150: Methods for NHP Preclinical Studies

ACUTE BIODISTRIBUTION & LASER-INDUCED CNV STUDIES

**NHP ACUTE BIODISTRIBUTION**

- **Eyes (N):** 4 NHP eyes
- **Dose (vg/eye):** 1E12
- **Study Duration:** 28 days
- **Endpoints:**
  - Tolerability
  - Aqueous Afibercept Expression
  - Retinal miRNA VEGF-C Expression

**NHP LASER-INDUCED CNV MODEL**

- **Eyes (N):** 42 NHP eyes
  - 14 per dose group
- **Dose (vg/eye):**
  - 1E11
  - 3E11
  - 1E12
- **Study Design:**
  - Day 0: 4D-150 administered
  - Day 28: Steroid taper completed
  - Day 42: Safety assessment followed-up by laser-induced CNV
  - Day 56: 2-week CNV assessment
  - Day 70: 4-week CNV assessment
  - 12-month: End of study (pending)
- **Endpoints:**
  - Tolerability
  - Suppression of Grade 4 CNV lesions
Intravitreal 4D-150: NHP Acute Biodistribution Study

HIGH AFLIBERCEPT AND VEGF-C miRNA EXPRESSION; NO EVIDENCE OF UVEITIS OR RETINAL ABNORMALITY

- 4D-150 resulted in high levels of aqueous aflibercept
- miRNA copies detected across all retinas
- No evidence of uveitis or retinal abnormality

Aqueous aflibercept level

### AFLB (ng/mL)

<table>
<thead>
<tr>
<th>4D-150 1E12 vg/eye</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
<tr>
<td>1000</td>
</tr>
<tr>
<td>2000</td>
</tr>
<tr>
<td>3000</td>
</tr>
<tr>
<td>4000</td>
</tr>
<tr>
<td>5000</td>
</tr>
<tr>
<td>6000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Retinal miRNA (Copies/ng RNA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4D-150 1E12 vg/eye</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>50000</td>
</tr>
<tr>
<td>100000</td>
</tr>
<tr>
<td>150000</td>
</tr>
</tbody>
</table>

4 eyes, 2 NHP, 4 weeks in life
Intravitreal 4D-150: Efficacy in NHP CNV Model

**100% SUPPRESSION OF CNV INCLUDING AT LOWEST DOSE OF 1E11 VG/EYE**

- **100% suppression of CNV (grade IV lesions), including at lowest dose of 1E11 vg/eye**

- **Day 42 ocular assessments prior to laser:**
  - 1E11 vg / eye, no uveitis or retinal abnormalities
  - 3E11 & 1E12 vg / eye, mild to moderate uveitis in a minority of NHP; no retinal abnormalities
  - Tapered 28-day steroid regimen
4D-150 Summary

DUAL-TRANSGENE, INTRAVITREAL GENE THERAPY INHIBITING FOUR DISTINCT VEGF FAMILY MEMBERS FOR WET AMD & DME

- Utilizes 4DMT’s targeted & evolved AAV vector R100 - invented for:
  - Routine intravitreal injection
  - Transgene expression across the entire surface area of the retina
  - Transgene expression in all major cell layers of the retina

- Designed for improved efficacy over other approaches:
  - VEGF (A&B) and PlGF (placental growth factor) inhibition via aflibercept expression and secretion
  - VEGF-C inhibition via RNAi

- Efficacy in NHP CNV model: 100% suppression with a single IVT dose, including at the lowest dose of 1E11 vg/eye

- Transgene expression in NHP acute biodistribution study: aflibercept & VEGF-C miRNA

- Clinical trial initiation in wet AMD & DME expected in second half of 2021